利伐沙班与华法林对非瓣膜性心房颤动患者的治疗效果

Efficacy of Rivaroxaban and Warfarin in the Treatment of Patients with Nonvalvular Atrial Fibrillation

目的:探讨利伐沙班与华法林对非瓣膜性心房颤动(NVAF)患者的疗效。方法:回顾性分析2021年1月—2023年1月日照市中医医院收治的60例NVAF患者的临床资料,按治疗方法不同将患者分为研究组与对照组,研究组采用利伐沙班片进行治疗,对照组采用华法林钠片进行治疗。比较两组的凝血功能、血清学指标、血液学异常现象发生情况及不良反应发生情况。结果:治疗后,研究组活化部分凝血活酶时间、凝血酶原时间、凝血酶时间均长于对照组,纤维蛋白原水平低于对照组,差异均有统计学意义(P<0.05)。治疗后,研究组D-二聚体、N末端B型利钠肽前体水平均低于对照组,差异均有统计学意义(P<0.05)。研究组异常出血发生率为6.67%,低于对照组的26.67%,差异有统计学意义(P<0.05)。研究组血栓发生率为6.67%,不良反应发生率为16.67%,相较于对照组的10.00%和23.33%,差异均无统计学意义(P>0.05)。结论:利伐沙班更有利于改善NVAF患者的凝血功能,纠正其血清学指标紊乱,降低异常出血发生率且较为安全。

Objective:To investigate the efficacy of Rivaroxaban and Warfarin in patients with nonvalvular atrial fibrillation(NVAF).Methods:Clinical data of 60 patients with NVAF admitted to Rizhao City Hospital of Traditional Chinese Medicine from January 2021 to January 2023 were retrospectively analysed.They were divided into a study group and a control group according to different treatment methods.The study group was treated with Rivaroxaban Tablets,the control group was treated with Warfarin Sodium Tablets.The coagulation function,serological indexes,occurrence of hematological abnormalities and adverse reactions were compared between the two groups.Results:After treatment,the activated partial thromboplastin time,prothrombin time and thrombin time of the study group were longer than those of the control group,the fibrinogen level was lower than that of the control group,with statistical significances(P<0.05).After treatment,the levels of D-dimer and N-terminal B-type natriuretic peptide precursors in the study group were lower than those in the control group,with statistical significance(P<0.05).The incidence of abnormal bleeding in the study group was 6.67%,which was lower than 26.67%in the control group,the difference was statistically significant(P<0.05).The incidence of blood embolism in the study group was 6.67%,the incidence of adverse reactions was 16.67%,which had no statistical significance compared with 10.00%and 23.33%in the control group(P>0.05).Conclusion:Rivaroxaban is more beneficial to improve the coagulation function of patients with NVAF,correct the disorder of serological indicators,reduce the incidence of abnormal bleeding,and relatively safe.